A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: To evaluate the impact of palbociclib treatment on health-related quality of life (HRQoL) in patients with hormone receptor-positive, human epidermal growth factor 2-negative advanced breast cancer (HR+/HER2- aBC) or metastatic breast cancer (mBC) in both the clinical and real-world setting. Materials & methods: A systematic literature review was conducted to identify clinical trials and real-world evidence studies up to June 2023 that reported HRQoL outcomes in patients with HR+/HER2- aBC or mBC treated with Palbociclib. Results: 15 unique studies reported across 35 records were identified. Of these, seven were randomized controlled trials (RCTs), three were single-arm clinical trials and five were real-world evidence (RWE) studies. HRQoL was generally found to be maintained in patients with HR+/HER2- aBC or mBC across RCTs, single-arm clinical trials and RWE studies. HRQoL measures across instruments, study types and line of therapy, were largely reported to be at least maintained if not improved from baseline among patients treated with palbociclib and were observed to be comparable or better in the palbociclib group versus monotherapy control arm in RCTs. Similar results were seen for treatment-related outcomes (e.g., sexual functioning, upset by hair loss, systemic therapy side effects etc.), and important individual patient outcomes, including pain, fatigue and physical functioning. Findings were also consistent across key clinical characteristics (visceral metastases, neutropenia), as well as patient populations often underrepresented in clinical trials (Asian patients, older adults). Conclusion: Overall, current evidence suggests that HRQoL is largely preserved with the addition of palbociclib to endocrine therapy in patients with HR+/HER2- aBC or mBC across study types and populations.
Plain language summary
What is this article about?
To fully understand the impact of treatment for advanced breast cancer that has spread to other parts of the body, or metastatic breast cancer, it is important to not only assess whether patients lived longer or if their disease improved (clinical improvement) but also patients' quality of life and experiences while on treatment. In this study, we identified and summarized all the publicly available evidence on the quality of life of patients with a certain type of metastatic breast cancer who were receiving treatment with a medication called palbociclib (a cyclin-dependent kinase 4/6 inhibitor). The type of breast cancer is advanced or metastatic hormone receptor-positive/human epidermal growth factor-negative breast cancer, also called HR-positive (or HR+)/HER2-negative (or HER2-) aBC or mBC.
What were the results?
We identified 15 studies that assessed quality of life during palbociclib treatment among patients with HR+/HER2- aBC or mBC, including both clinical trials and real-world evidence. Quality of life was generally maintained, or did not worsen, with palbociclib treatment across all studies evaluated. Similar results were found for symptoms often associated with breast cancer treatments (e.g., sexual functioning, upset by hair loss, systemic therapy side effects) and other important breast cancer patient symptoms and measures, such as physical functioning, pain and fatigue. These results were also consistent across specific populations, such as Asians and the elderly, and across patients with various other medical conditions in addition to breast cancer, such as visceral metastases (cancer spreading to specific locations such as the liver, lungs and brain etc.) and neutropenia (low levels of a specific type of white blood cells called neutrophils).
What do the results mean?
The addition of palbociclib to other traditional breast cancer therapies, such as endocrine therapy, in patients with HR+/HER2- aBC or mBC, while providing a clinical benefit, does not negatively impact or worsen quality of life.
Supplementary Material
File (supplementary materials.docx)
- Download
- 372.33 KB
References
Papers of special note have been highlighted as: • of interest
1.
Sitlinger A, Zafar SY. Health-related quality of life: the impact on morbidity and mortality. Surg. Oncol. Clin. N. Am. 27(4), 675–684 (2018).
2.
Cherny NI, Sullivan R, Dafni U et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann. Oncol. 26(8), 1547–1573 (2015).
3.
Partridge AH, Rumble RB, Carey LA et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 32(29), 3307–3329 (2014).
4.
Cardoso F, Paluch-Shimon S, Senkus E et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann. Oncol. 31(12), 1623–1649 (2020).
5.
US Food and Drug Administration. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims 2009 Contract No.: FDA-2006-D-0362. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims
6.
US Food and Drug Administration. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics Guidance for Industry. 2018 Contract No.: FDA-2005-D-0225. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics
7.
US Food and Drug Administration. Quantifying physical function in cancer patients undergoing chemotherapy using clinician-reported, patient-reported, and wearable device data sources. https://www.fda.gov/science-research/advancing-regulatory-science/quantifying-physical-function-cancer-patients-undergoing-chemotherapy-using-clinician-reported
8.
Irvin W Jr, Muss HB, Mayer DK. Symptom management in metastatic breast cancer. Oncologist 16(9), 1203–1214 (2011).
9.
US Food and Drug Administration. The Voice of the Patient: Breast Cancer. 1–25 (2015). https://www.fda.gov/media/93924/download
10.
US Food and Drug Administration. Palbociclib (IBRANCE) (2023). https://www.fda.gov/drugs/resources-information-approved-drugs/palbociclib-ibrance#:~:text=FDA%20granted%20palbociclib%20accelerated%20approval,based%20therapy%20in%20postmenopausal%20women
11.
Finn RS, Martin M, Rugo HS et al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med. 375(20), 1925–1936 (2016).
12.
Turner NC, Slamon DJ, Ro J et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N. Engl. J. Med. 379(20), 1926–1936 (2018).
13.
Xu B, Hu X, Li W et al. Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4. Eur. J. Cancer 175, 236–245 (2022).
14.
Shen L, Zhou J, Chen Y et al. Treatment patterns, effectiveness, and patient-reported outcomes of palbociclib therapy in Chinese patients with advanced breast cancer: a multicenter ambispective real-world study. Cancer Med. 11(22), 4157–4168 (2022).
15.
Carola E, Pulido M, Falandry C et al. First-line systemic treatment with palbociclib in women aged ≥70 years presenting with hormone receptor-positive advanced breast cancer: results from the PALOMAGE program. J. Clin. Oncol. 41(Suppl. 16), 1018 (2023).
16.
Karuturi MS, Rocque GB, Cappelleri JC et al. Abstract P1-18-25: real-world quality of life (QoL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC) treated with palbociclib: A patient-reported outcome (PRO) analysis from POLARIS. Cancer Res. 82(Suppl. 4), P1-18-25 (2022).
17.
Abola MV, Prasad V, Jena AB. Association between treatment toxicity and outcomes in oncology clinical trials. Ann. Oncol. 25(11), 2284–2289 (2014).
18.
Seeger JD, Nunes A, Loughlin AM. Using RWE research to extend clinical trials in diabetes: an example with implications for the future. Diabetes Obes. Metab. 22(Suppl. 3), 35–44 (2020).
19.
Chodankar D. Introduction to real-world evidence studies. Perspect. Clin. Res. 12(3), 171–174 (2021).
20.
Cardoso F, Cella D, Velikova G et al. Quality-of-life methodology in hormone receptor-positive advanced breast cancer: current tools and perspectives for the future. Cancer Treat. Rev. 102, 102321 (2022).
21.
Di Lauro V, Barchiesi G, Martorana F et al. Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review. ESMO Open 7(6), 100629 (2022).
• Systematic literature review summarizing health-related quality of life (HRQoL) results of breast cancer patients of any stage treated with CDK4/6 inhibitor, including palbociclib, in comparison to the present review.
22.
Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLOS Med. 18(3), e1003583 (2021).
23.
Higgins J, Thomas J, Chandler J et al. (Eds). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). (2022). http://www.training.cochrane.org/handbook
24.
Booth A, Clarke M, Dooley G et al. The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Syst. Rev. 1(1), 2 (2012).
25.
McGowan J, Sampson M, Sazwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. J. Clin. Epidemiol. 75, 40–46 (2016).
26.
DistillerSR. Version 2.35. DistillerSR Inc.; (2022). https://www.distillersr.com/
27.
Centre for Review and Dissemination. Systematic Reviews: CRD's guidance for undertaking reviews in health care. (2009). https://www.york.ac.uk/media/crd/Systematic_Reviews.pdf
28.
Wells GA, Shea B, O'Connell D et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Oxford (2000). https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
29.
Pal R, Banerjee M, Yadav U, Bhattacharjee S. Statin use and clinical outcomes in patients with COVID-19: an updated systematic review and meta-analysis. Postgrad. Med. J. 98(1159), 354–359 (2022).
30.
Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021).
31.
Tibau A, Martínez MT, Ramos M et al. Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial. Ther. Adv. Med. Oncol. 15, 17588359221148921 (2023).
• International phase II trial of first line palbociclib plus fulvestrant versus placebo plus fulvestrant that reports relevant HRQoL data (EORTC QLQ-C30, EORTC QLQ-BR23) included within this review.
32.
Bell T, Crown JP, Lang I et al. Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment. Curr. Med. Res. Opin. 32(5), 959–965 (2016).
33.
Rugo HS, Dieras V, Gelmon KA et al. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann. Oncol. 29(4), 888–894 (2018).
34.
Rugo HS, Finn RS, Dieras V et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res. Treat. 174(3), 719–729 (2019).
• International phase III trial of first-line palbociclib plus letrozile versus placebo plus letrozole that reports relevant HRQoL data (FACT-B, FACT-G) included within this review.
35.
Im SA, Mukai H, Park IH et al. Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer: results from the phase III, randomized PALOMA-2 study. J. Glob. Oncol. 5, 1–19 (2019).
36.
Harbeck N, Iyer S, Turner N et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann. Oncol. 27(6), 1047–1054 (2016).
• International phase III trial of any line palbociclib plus fulvestrant versus placebo plus fulvestrant that reports relevant HRQoL data (EORTC QLQ-C30, EORTC QLQ-BR23) included within this review.
37.
Iwata H, Im SA, Masuda N et al. PALOMA-3: phase III trial of fulvestrant with or without palbociclib in premenopausal and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer that progressed on prior endocrine therapy-safety and efficacy in Asian patients. J. Glob. Oncol. 3(4), 289–303 (2017).
38.
Turner NC, Ro J, Andre F et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 373(3), 209–219 (2015).
39.
Turner NC, Finn RS, Martin M et al. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Ann. Oncol. 29(3), 669–680 (2018).
40.
Rugo HS, Turner NC, Finn RS et al. Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. Eur. J. Cancer 101, 123–133 (2018).
41.
Martin M, Zielinski C, Ruiz-Borrego M et al. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL. Ann. Oncol. 32(4), 488–499 (2021).
42.
Kahan Z, Gil-Gil M, Ruiz-Borrego M et al. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: patient-reported outcomes in the PEARL study. Eur. J. Cancer 156, 70–82 (2021).
• International phase III trial of any line palbociclib plus endocrine therapy versus capecitabine that reports relevant HRQoL data (EORTC QLQ-C30, EORTC QLQ-BR23, EQ-5D-3L) included within this review.
43.
Lee S, Im SA, Kim GM et al. Patient-reported outcomes of palbociclib plus exemestane with GnRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer: a prospective, open-label, randomized phase ll trial (KCSG-BR 15-10). Cancers (Basel) 12(11), 3265 (2020).
• Phase III trial of any line palbociclib plus endocrine therapy and gonadotropin hormone-releasing hormone agonist versus capecitabine in premenopausal women that reports relevant HRQoL data (EORTC QLQ-C30) included within this review.
44.
Loi S, Karapetis CS, McCarthy N et al. Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: an expanded access study in Australia and India. Asia Pac. J. Clin. Oncol. 18(6), 560–569 (2022).
45.
Takahashi M, Masuda N, Nishimura R et al. Palbociclib-letrozole as first-line treatment for advanced breast cancer: updated results from a Japanese phase II study. Cancer Med. 9(14), 4929–4940 (2020).
46.
Stearns V, Brufsky AM, Verma S et al. Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. Clin. Breast Cancer 18(6), e1239–e1245 (2018).
47.
Richardson D, Zhan L, Mahtani R et al. A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application. Breast Cancer Res. Treat. 187(1), 113–124 (2021).
48.
Rugo H, Dieras V, Gelmon KA et al. Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naïve postmenopausal patients with ER+ HER2- metastatic breast cancer (MBC): results from PALOMA-2. Ann. Oncol. 27(Suppl. 6), vi69 (2016).
49.
Loibl S, DeMichele A, Turner NM et al. Impact of palbociclib plus fulvestrant on patient reported general health status compared with fulvestrant alone in HR+, HER2- metastatic breast cancer. Ann. Oncol. 27(Suppl. 6), vi80 (2016).
50.
Hu X, Broughton E, Li W et al. 218P Patient-reported quality of life in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) treated with palbociclib (PAL) plus letrozole (LET): Results from PALOMA-4. Ann. Oncol. 33(Suppl. 7), S637 (2022).
51.
Tibau A, Martinez MT, Ramos M et al. 94MO Quality of life (QoL) with fulvestrant (FUL)/palbociclib (PAL) versus FUL/placebo (PBO) in postmenopausal women with hormone receptor (HR)+/HER2- endocrine sensitive advanced breast cancer (ABC): Results from GEICAM/2014-12 (FLIPPER) study. Ann. Oncol. 32(Suppl. 2), S63 (2021).
52.
Rocque G, Blum JL, Ji Y et al. 266P Real-world quality of life (QoL) in patients with HR+/HER2-advanced breast cancer (ABC) treated with palbociclib: final clinical outcome assessment (COA) analysis from POLARIS. Ann. Oncol. 33(Suppl. 7), S659 (2022).
53.
Rocque GB, Blum JL, Montero A et al. Real-world quality of life (QoL) in black, indigenous and people of color (BIPOC) treated with palbociclib (PAL) and endocrine therapy for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): a subgroup analysis from POLARIS. J. Clin. Oncol. 39(Suppl. 15), 1071 (2021).
54.
Rocque G, Blum JL, Montero A et al. Abstract PD10-03: quality of life in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer treated with palbociclib in real-world practice settings. Cancer Res. 80(Suppl. 4), PD10-03 (2020).
55.
Brain E, Pulido M, Paillaud E et al. Abstract P1-18-04: feasibility of palbociclib in women aged 70 and older with resistant and/or pretreated advanced breast cancer in the PALOMAGE study. Cancer Res. 82(Suppl. 4), P1-18-04 (2022).
56.
Rahman SA, Mayer EL, Poort H et al. Abstract P4-09-01: incidence of patient-reported fatigue developing in patients receiving palbociclib and endocrine therapy for advanced HR+ HER2- breast cancer. Cancer Res. 82(Suppl. 4), P4-09-1 (2022).
57.
European Union Clinical Trials Register. Phase 1/2, Open-Label, Randomized Study of the Safety, Efficacy, and Pharmacokinetics of Letrozole Plus PD 0332991 (Oral CDK 4/6 Inhibitor) and Letrozole Single Agent for the First-Line Treatment of ER Positive, HER2 Negative Advanced Breast Cancer in Postmenopausal Women. https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002392-27/results
58.
United States National Library of Medicine. A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2). https://beta.clinicaltrials.gov/study/NCT01740427
59.
European Union Clinical Trials Register. Multicenter, randomized, double-blind, placebo controlled, phase III trial of fulvestrant (Faslodex) with or without PD-0332991 (palbociclib) ± goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer whose disease progressed after prior endocrine therapy. https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002580-26/results
60.
United States National Library of Medicine. Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor + HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3). https://beta.clinicaltrials.gov/study/NCT01942135
61.
United States National Library of Medicine. A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo + Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]. https://beta.clinicaltrials.gov/study/NCT02297438
62.
United States National Library of Medicine. A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer. https://beta.clinicaltrials.gov/study/NCT01684215
63.
Tibau A, Martinez MT, Ramos M et al. Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial. Ther. Adv. Med. Oncol. 15, 17588359221148921 (2023).
64.
European Union Clinical Trials Register. Multicenter, randomized, double-blind, placebocontrolled, phase III trial of fulvestrant (FASLODEX) with or without PD-0332991 (palbociclib) ± goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer whose disease progressed after prior endocrine therapy. https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002580-26/results
65.
Bottomley A, Reijneveld JC, Koller M et al. Current state of quality of life and patient-reported outcomes research. Eur. J. Cancer 121, 55–63 (2019).
66.
US Food and Drug Administration. Assessment of the use of patient experience data in regulatory decision-making. Lexington, MA, USA (2021).
67.
American Cancer Society. Breast Cancer Facts & Figures 2019-2020. Atlanta, GA, USA (2019).
68.
Serra F, Lapidari P, Quaquarini E, Tagliaferri B, Sottotetti F, Palumbo R. Palbociclib in metastatic breast cancer: current evidence and real-life data. Drugs Context 8, 212579 (2019).
69.
Kiesewetter B, Dafni U, de Vries EGE et al. ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0. Ann. Oncol. 34(9), 734–771 (2023).
70.
European Society for Medical Oncology. ESMO-MCBS Scorecards: palbociclib. https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-for-solid-tumours/esmo-mcbs-scorecards?mcbs_score_cards_form%5BsearchText%5D=palbociclib
71.
European Society for Medical Oncology. ESMO-MCBC Scorecard: Palbociclib PALOMA-3. https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-for-solid-tumours/esmo-mcbs-scorecards/scorecard-6-1
72.
DeMichele A, Cristofanilli M, Brufsky A et al. Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. Breast Cancer Res. 23(1), 37 (2021).
73.
Zhou Z, Tang DH, Xie J, Ayyagari R, Wu E, Niravath PA. Systematic literature review of the impact of endocrine monotherapy and in combination with targeted therapy on quality of life of postmenopausal women with HR+/HER2-advanced breast cancer. Adv. Ther. 34(12), 2566–2584 (2017).
• Systematic literature review of randomized controlled trials (RCTs) investigating the impact of targeted therapy and endocrine therapy on QoL outcomes in patients with HR+/HER2- advanced breast cancer, in comparison to the present review.
74.
Kolben T, Bardenhewer M, Kolben TM et al. Metastatic breast cancer: is there a differential therapy efficacy between visceral and non-visceral metastatic breast cancer? Breast Care (Basel) 15(5), 527–533 (2020).
75.
Lavery L, DiSogra K, Lea J et al. Risk factors associated with palbociclib-induced neutropenia in patients with metastatic breast cancer. Support. Care Cancer 30(12), 9803–9809 (2022).
76.
Moscetti L, Sperduti I, Frassoldati A et al. Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: regulatory aspects and clinical impact in Europe. Breast 59, 232–238 (2021).
77.
Harbeck N, Bartlett M, Spurden D et al. CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies. Future Oncol. 17(16), 2107–2122 (2021).
• Systematic literature review of RWE studies evaluating CDK-4/6 inhibitors for the treatment of patients with HR+/HER2- advanced or metastatic breast cancer, highlighting the lack of RWE studies for CDK-4/6 inhibitors other than palbociclib.
78.
Kaufman PA, Toi M, Neven P et al. Health-related quality of life in MONARCH 2: abemaciclib plus fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. Oncologist 25(2), e243–e251 (2020).
79.
Goetz MP, Martin M, Tokunaga E et al. Health-related quality of life in MONARCH 3: abemaciclib plus an aromatase inhibitor as initial therapy in HR+, HER2-advanced breast cancer. Oncologist 25(9), e1346–e1354 (2020).
80.
Fasching PA, Bardia A, Nusch A et al. 276O Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2, -3, and -7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer (ABC). Ann. Oncol. 31(Suppl. 4), S350–S351 (2020).
81.
Cardoso F, Cella D, Velikova G et al. Quality-of-life methodology in hormone receptor-positive advanced breast cancer: current tools and perspectives for the future. Cancer Treat. Rev. 102, 102321 (2022).
Information & Authors
Information
Published In
Copyright
© 2024 Pfizer. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 9 July 2024
Accepted: 30 August 2024
Published online: 10 September 2024
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib. (2024) Journal of Comparative Effectiveness Research. DOI: 10.57264/cer-2024-0111
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Reshma Mahtani, Beata Korytowsky, Chloe Grace Rose, Maria Jakobsson, Joseph Cappelleri, Katie Lewis, Annabel Lambert, Chloe Hammond, Carmen Criscitiello, Real-world treatment patterns and sequencing in patients with advanced / metastatic HR+/HER2- breast cancer in Europe and the United States, The Breast, 10.1016/j.breast.2026.104732, 86, (104732), (2026).
- Rutuja Suryawanshi, Anumol Joseph, Rajkumar Malayandi, In silico designing of palbociclib loaded PLGA long-acting intramuscular injection for palliative therapy of HR+/HER2− metastatic breast cancer, Journal of Pharmacy and Pharmacology, 10.1093/jpp/rgag028, 78, 3, (2026).
- Ibrahim Bayav, Sevda Sağ, Huriye Ergezgin, Yavuz Dodurga, Ayse Gaye Tomatir, Possible TLR-mediated immunostimulatory effect of Palbociclib in breast cancer, Molecular Biology Reports, 10.1007/s11033-025-11282-9, 53, 1, (2025).
- Nadia Harbeck, Adam Brufsky, Chloe Grace Rose, Beata Korytowsky, Connie Chen, Krista Tantakoun, Endri Jazexhi, Do Hoang Vien Nguyen, Meaghan Bartlett, Imtiaz A. Samjoo, Timothy Pluard, Real-world effectiveness and safety of CDK4/6i in elderly and BIPOC patients with HR+/HER2- advanced/metastatic breast cancer: an updated systematic literature review, Frontiers in Oncology, 10.3389/fonc.2025.1577075, 15, (2025).
- Tong Gao, Ying Sun, Ping Leng, Donghua Liu, Qie Guo, Jing Li, CDK4/6 inhibitors in breast cancer therapy: mechanisms of drug resistance and strategies for treatment, Frontiers in Pharmacology, 10.3389/fphar.2025.1549520, 16, (2025).
- Nadia Harbeck, Adam Brufsky, Chloe Grace Rose, Beata Korytowsky, Connie Chen, Krista Tantakoun, Endri Jazexhi, Do Hoang Vien Nguyen, Meaghan Bartlett, Imtiaz A. Samjoo, Timothy Pluard, Real-world effectiveness of CDK4/6i in first-line treatment of HR+/HER2− advanced/metastatic breast cancer: updated systematic review, Frontiers in Oncology, 10.3389/fonc.2025.1530391, 15, (2025).
- Gaojian He, Xuemei Huang, Yun Dong, Kun Chen, Xuefeng He, Meitong Pan, Weicheng Zeng, Xiaolan Yu, Jiyi Xia, Preliminary investigation on the mechanism of baicalein regulating the effects of Nischarin on invasion and apoptosis of human breast cancer cells MCF-7 through Wnt3α/β-catenin pathway, International Immunopharmacology, 10.1016/j.intimp.2024.113262, 143, (113262), (2024).
- Gabrielle B. Rocque, Joanne L. Blum, Yan Ji, Timothy Pluard, John Migas, Shailendra Lakhanpal, Erin Jepsen, Eric Gauthier, Yao Wang, Monica Z. Montelongo, Joseph C. Cappelleri, Meghan S. Karuturi, Debu Tripathy, Real-world quality-of-life of patients with HR+/HER2− advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS, Breast Cancer Research and Treatment, 10.1007/s10549-024-07524-2, 209, 3, (613-627), (2024).
- Agnieszka Łupicka-Słowik, Federica Cossu, Marcin Sieńczyk, Palbociclib as an Antitumor Drug: A License to Kill, Molecules, 10.3390/molecules29225334, 29, 22, (5334), (2024).